Table 2.
Additional characteristics among COVID-19 cancer patients with respiratory failure. (n = 65)
| n (%) | |
|---|---|
| Cancer site | |
| Hematological | 8 (12.3) |
| Lymphoma | 7(10.8) |
| Myeloproliferative neoplasm | 1(1.5) |
| Solid tumors | 57 (87.7) |
| Breast | 4(6.2) |
| Prostate | 5(7.7) |
| Gastrointestinal | 10(15.4) |
| Hepatocellular carcinoma | 4(6.2) |
| Biliary tract | 1(1.5) |
| Pancreas | 1(1.5) |
| Lung | 16(24.6) |
| Gynecological | 4(6.2) |
| Head and neck | 3(4.6) |
| Genitourinary | 5(7.7) |
| Musculoskeletal | 1(1.5) |
| Central nervous system | 2(3.1) |
| Malignancy of unknown origin | 1(1.5) |
| Cancer treatment within 4 weeks of COVID-19 diagnosis | 34 (52.3) |
| ICI* combination | 4 (6.2) |
| ICI + chemotherapy | 3 (4.6) |
| ICI + TKI* | 1(1.5) |
| Cytotoxic chemotherapy | 16 (24.6) |
| Intravenous chemotherapy | 12 (18.5) |
| Oral chemotherapy | 4 (6.2) |
| Endocrine therapy | 1 (1.5) |
| TKI | 9 (13.8) |
| Monoclonal antibody | 3 (4.6) |
| Anti-VEGF* agents | 1 (1.5) |
*ICI immune checkpoint inhibitor, TKI tyrosine kinase inhibitor, VEGF vascular endothelial growth factor